Skip to main content
Clinical Trials/NCT05377515
NCT05377515
Completed
Not Applicable

Evaluation of Visual Outcomes in Patients With Complex Corneas Implanted With the IC-8 IOL

AcuFocus, Inc.1 site in 1 country21 target enrollmentFebruary 10, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cataract
Sponsor
AcuFocus, Inc.
Enrollment
21
Locations
1
Primary Endpoint
Monocular UCNVA
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to evaluate visual outcomes in patients with complex corneas who have been previously implanted with the IC-8 IOL after cataract removal.

Detailed Description

This will be a prospective, non-randomized, single-arm, single-visit, single-center, clinical study in up to 40 patients previously contralaterally implanted with the IC-8 IOL at one clinical site in Singapore. The purpose of this study is to to evaluate visual outcomes in patients with complex corneas who have been previously implanted with the IC-8 IOL after cataract removal. The co-primary study endpoints are monocular uncorrected distance, intermediate, near visual acuities.

Registry
clinicaltrials.gov
Start Date
February 10, 2022
End Date
December 30, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Minimum 22 years of age;
  • Able to comprehend and have signed a statement of informed consent;
  • Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visit(s);
  • Having complex corneas prior to cataract surgery;
  • Previous cataract surgery and IC-8 IOL implantation in the eye (implanted for 3 months or longer prior to study participation).

Exclusion Criteria

  • Baseline visual acuity worse than 20/25 BCDVA in either eye;
  • Presence of ocular abnormalities or conditions other than corneal irregularities that could confound the study outcome(s), such as:
  • Strabismus or amblyopia
  • Retinal or macular abnormalities
  • Recurrent and/or persistent ocular inflammation
  • Known pathology that may affect visual acuity to a level worse than 20/25 BCDVA
  • Previous intraocular surgery, except cataract surgery, pterygium surgery, or corneal procedures (other than corneal-cross linking);
  • Previous corneal cross-linking procedure with any corneal haze;
  • Conditions requiring planned ocular surgical intervention, except Nd:YAG capsulotomy;
  • Severe dry eye or other conditions (such as hormonal fluctuations) that could lead to unstable refraction and/or visual acuity measurements or eye discomfort even with ocular lubricants or dry eye medication;

Outcomes

Primary Outcomes

Monocular UCNVA

Time Frame: 3 Months

not worse than 0.3 logMAR

Monocular UCDVA

Time Frame: 3 Months

0.3 logMAR or better

Monocular UCIVA

Time Frame: 3 Months

0.3 logMAR or better

Study Sites (1)

Loading locations...

Similar Trials